COVID-19

Providing Test Services to Better Understand COVID-19 Immune Response

Measuring antibody levels allows tracking of an individual’s immune response.

ProterixBio offers the highest quality antibody testing services through our CLIA-Certified high-complexity clinical testing laboratory. Our lead test, which was licensed from a major medical research center, detects antibodies to the Receptor Binding Domain (RBD) of the spike protein of the SARS-CoV-2 virus, which are associated with neutralizing activity and relevant to potential development of immunity. The test output is a numerical index related to the levels of antibodies to better understand an individual’s immune response.

ProterixBio’s products are critical to COVID-19 response efforts: vaccines, convalescent plasma, back-to-work/school programs and public health surveillance.

View our COVID-19 Serology Test Menu

Antibody Testing Plays an Important Role in the Response to COVID-19

Antibody measurements to monitor immune response are an important complement to SARS-CoV-2 testing. Active infections are diagnosed using nucleic acid or antigen tests that detect viral particles in samples from the respiratory tract or saliva. Antibodies measured in blood have multiple important use cases:

  • Determine prior exposure to SARS-CoV-2, confirm cases that were missed by PCR or antigen tests
  • Identify asymptomatic cases and potential transmission paths
  • Track the overall prevalence of COVID-19 in an organization or a community
  • Monitor the adaptive immune response over time, which is critical for vaccine and convalescent plasma programs

About ProterixBio

ProterixBio is a licensed high-complexity clinical testing laboratory that develops and commercializes diagnostic solutions that address critical unmet needs in population health and chronic care. An area of focus has been vulnerable populations such as those with chronic obstructive pulmonary disease, diabetes and cardiovascular disease. The company has developed algorithms utilizing combinations of blood-based biomarkers for identifying individuals at high risk for severe outcomes. ProterixBio maintains a rigorous approach to test development that includes collaborating with leading academic medical centers and validating assays in large, carefully curated cohorts. ProterixBio is headquartered in Billerica, MA.

Learn more about ProterixBio

Latest Updates

Press Releases View All

For more information: